Diffuse Panbronchiolitis

Seminars in Respiratory and Critical Care Medicine

Volumn 24, Issue 5, 2003, Pages 607-617

  Kudoh, Shoji ^a   Keicho, Naoto ^b  

^a NIPPON MEDICAL SCHOOL   (Japan)

^b NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

Author keywords

Chronic airway infection; Macrolides

Indexed keywords

AZITHROMYCIN; CLARITHROMYCIN; ERYTHROMYCIN; JOSAMYCIN; MACROLIDE; ROXITHROMYCIN;

ANTIBIOTIC THERAPY; ASIAN; BACTERIAL VIRULENCE; BACTERICIDAL ACTIVITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; DIFFERENTIAL DIAGNOSIS; DIFFUSE PANBRONCHIOLITIS; DRUG MECHANISM; HUMAN; INFLAMMATORY CELL; LYMPHOCYTE; MACROPHAGE; MUCUS SECRETION; NEUTROPHIL; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; PSEUDOMONAS AERUGINOSA; RESPIRATORY EPITHELIUM; RESPIRATORY TRACT INFECTION; REVIEW; SIDE EFFECT; SUPERINFECTION;

EID: 0348011688     PISSN: 10693424     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-815608     Document Type: Review

References (109)

1. Honma H. Diffuse panbronchiolitis [in Japanese]. Nihon Kyobu Shikkan Gakkai Zasshi 1975;13:383-395
2. Yamanaka A, Saiki S, Tamura S, Saito K. Problems in chronic obstructive bronchial diseases, with special reference to diffuse panbronchiolitis [in Japanese]. Naika 1969;23:442-451
3. Izumi T, Doi O, Nobechi A, et al. Nation-wide survey of diffuse panbronchiolitis [author's transl] [in Japanese]. Annual Report on the study of interstitial lung disease in 1982. Tokyo:. Grant-in Aid from the Ministry of Health and Welfare of Japan; 1983;3-41
4. Homma H, Yamanaka A, Tanimoto S, et al. Diffuse panbronchiolitis: a disease of the transitional zone of the lung. Chest 1983;83:63-69
5. Kudoh S, Uetake T, Hagiwara K, et al. Clinical effects of low-dose long-term erythromycin chemotherapy on diffuse panbronchiolitis [in Japanese]. Nihon Kyobu Shikkan Gakkai Zasshi 1987;25:632-642
6. Homma H. Diffuse panbronchiolitis. Jpn J Med 1986;25:329-334
7. Kim YW, Han SK, Shim YS, et al. The first report of diffuse panbronchiolitis in Korea: five case reports. Intern Med 1992;31:695-701
8. Chu YC, Yeh SZ, Chen CL, Chen CY, Chang CY, Chiang CD. Diffuse panbronchiolitis: report of a case. J Formos Med Assoc 1992;91:912-915
9. Tredaniel J, Cazals-Hatem D, Zalcman G, d'Agay MF, Capron F. Diffuse panbronchiolitis: efficacy of low-dose erythromycin. Respir Med 1994;88:479-480
10. Homer RJ, Khoo L, Smith GJ. Diffuse panbronchiolitis in a Hispanic man with travel history to Japan. Chest 1995;107:1176-1178
11. Hu H, Liu Y, Cai Z, Chen L. A case of diffuse panbronchiolitis. Chin Med J (Engl) 1996;109:949-952
12. Zainudin BM, Roslina AM, Fadilah SA, Samad SA, Sufarlan AW, Isa MR. A report of the first three cases of diffuse panbronchiolitis in Malaysia. Med J Malaysia 1996;51:136-140
13. Wang H, Sun T, Miao J, Li Y. A definite case of diffuse panbronchiolitis diagnosed by open lung biopsy. Chin Med J (Engl) 1998;111:864
14. Tsang KW, Ooi CG, Ip MS, et al. Clinical profiles of Chinese patients with diffuse panbronchiolitis. Thorax 1998;53:274-280
15. Poh SC, Wang YT, Wang WY. Diffuse panbronchiolitis: a case report. Singapore Med J 2001;42:271-274
16. Randhawa P, Hoagland MH, Yousem SA. Diffuse panbronchiolitis in North America: report of three cases and of the literature. Am J Surg Pathol 1991;15:43-47
17. Poletti V, Patelli M, Poletti G, Bertanti T, Spiga L. Diffuse panbronchiolitis observed in an Italian male. Sarcoidosis 1992;9:67-69
18. Fitzgerald JE, King TE Jr, Lynch DA, Tuder RM, Schwarz MI. Diffuse panbronchiolitis in the United States. Am J Respir Crit Care Med 1996;154(2 Pt 1):497-503
19. Schulte W, Szrepka A, Bauer PC, Guzman J, Costabel U. Diffuse panbronchiolitis: a rare differential diagnosis of chronic obstructive lung disease [in German]. Dtsch Med Wochenschr 1999;124:584-588
20. Chantarotorn S, Palwatwichai A, Vattanathum A, Tantamacharik D. Diffuse panbronchiolitis, the first case reports in Thailand. J Med Assoc Thai 1999;82:833-838
21. Gulhan M, Erturk A, Kurt B, et al. Diffuse panbronchiolitis observed in a white man in Turkey. Sarcoidosis Vasc Diffuse Lung Dis 2000;17:292-296
22. Claxton S, Markos J. A case of diffuse panbronchiolitis. Aust N Z J Med 2000;30:99-100
23. Martinez JA, Guimaraes SM, Ferreira RG, Pereira CA. Diffuse panbronchiolitis in Latin America. Am J Med Sci 2000;319:183-185
24. Fisher MS Jr, Rush WL, Rosado-de-Christenson ML, et al. Diffuse panbronchiolitis: histologic diagnosis in unsuspected cases involving North American residents of Asian descent. Arch Pathol Lab Med 1998;122:156-160
25. Brugiere O, Milleron B, Antoine M, Carette MF, Philippe C, Mayaud C. Diffuse panbronchiolitis in an Asian immigrant. Thorax 1996;51:1065-1067
26. Corne J. Diffuse panronchiolitis: a new Japanese export? Lancet 1996;348:1465-1466
27. Sugiyama Y, Kudoh S, Maeda H, Suzaki H, Takaku F. Analysis of HLA antigens in patients with diffuse panbronchiolitis. Am Rev Respir Dis 1990;141:1459-1462
28. Keicho N, Tokunaga K, Nakata K, et al. Contribution of HLA genes to genetic predisposition in diffuse panbronchiolitis. Am J Respir Crit Care Med 1998;158:846-850
29. Park MH, Kim YW, Yoon HI, et al. Association of HLA class I antigens with diffuse panbronchiolitis in Korean patients. Am J Respir Crit Care Med 1999;159:526-529
30. Keicho N, Ohashi J, Tamiya G, et al. Fine localization of a major disease-susceptibility locus for diffuse panbronchiolitis. Am J Hum Genet 2000;66:501-507
31. Hoiby N. Diffuse panbronchiolitis and cystic fibrosis: East meets West. Thorax 1994;49:531-532
32. Akai S, Okayama H, Shimura S, Tanno Y, Sasaki H, Takishima T. Delta F508 mutation of cystic fibrosis gene is not found in chronic bronchitis with severe obstruction in Japan. Am Rev Respir Dis 1992;146:781-783
33. Ichikawa Y, Ninomiya H, Koga H, et al. Erythromycin reduces neutrophils and neutrophil-derived elastolytic-like activity in the lower respiratory tract of bronchiolitis patients. Am Rev Respir Dis 1992;146:196-203
34. Kadota J, Sakito O, Kohno S, et al. A mechanism of erythromycin treatment in patients with diffuse panbronchiolitis. Am Rev Respir Dis 1993;147:153-159
35. Yoshimura K, Iizuka S, Anzai C, et al. Diffuse panbronchiolitis is closely associated with mutations of the CFTR gene. Am J Respir Crit Care Med 2000;161:A77
36. Sugiyama Y, Kudoh S, Kitamura S. A case of the bare lymphocyte syndrome with clinical manifestations of diffuse panbronchiolitis [in Japanese]. Nihon Kyobu Shikkan Gakkai Zasshi 1989;27:980-983
37. Donato L, de la Salle H, Hanau D, et al. Association of HLA class I antigen deficiency related to a TAP2 gene mutation with familial bronchiectasis. J Pediatr 1995;127:895-900
38. Teisserenc H, Schmitt W, Blake N, et al. A case of primary immunodeficiency due to a defect of the major histocompatibility gene complex class I processing and presentation pathway. Immunol Lett 1997;57:183-187
39. Furukawa H, Murata S, Yabe T, et al. Splice acceptor site mutation of the transporter associated with antigen processing-1 gene in human bare lymphocyte syndrome. J Clin Invest 1999;103:755-758
40. Raghavan M. Immunodeficiency due to defective antigen processing: the molecular basis for type 1 bare lymphocyte syndrome. J Clin Invest 1999;103:595-596
41. Azuma A, Keicho N, Furukawa H, Yabe T, Kudoh S. Prolonged survival of a bare lymphocyte syndrome type I patient with diffuse panbronchiolitis treated with erythromycin. Sarcoidosis Vasc Diffuse Lung Dis 2001;18:312-313
42. Maeda M, Saiki S, Yamanaka A. Serial section analysis of the lesions in diffuse panbronchiolitis. Acta Pathol Jpn 1987;37:693-704
43. Iwata M, Colby TV, Kitaichi M. Diffuse panbronchiolitis: diagnosis and distinction from various pulmonary diseases with centrilobular interstitial foam cell accumulations. Hum Pathol 1994;25:357-363
44. Sato A, Chida K, Iwata M, Hayakawa H. Study of bronchus-associated lymphoid tissue in patients with diffuse panbronchiolitis. Am Rev Respir Dis 1992;146:473-478
45. Mukae H, Kadota J, Kohno S, et al. Increase in activated CD8+ cells in bronchoalveolar lavage fluid in patients with diffuse panbronchiolitis. Am J Respir Crit Care Med 1995;152:613-618
46. Ichikawa Y, Koga H, Tanaka M, Nakamura M, Tokunaga N, Kaji M. Neutrophilia in bronchoalveolar lavage fluid of diffuse panbronchiolitis. Chest 1990;98:917-923
47. Oda H, Kadota J, Kohno S, Hara K. Erythromycin inhibits neutrophil chemotaxis in bronchoalveoli of diffuse panbronchiolitis. Chest 1994;106:1116-1123
48. Oda H, Kadota J, Kohno S, Hara K. Leukotriene B4 in bronchoalveolar lavage fluid of patients with diffuse panbronchiolitis. Chest 1995;108:116-122
49. Sakito O, Kadota J, Kohno S, Abe K, Shirai R, Hara K. Interleukin-1 beta, tumor necrosis factor alpha, and interleukin 8 in bronchoalveolar lavage fluid of patients with diffuse panbronchiolitis: a potential mechanism of macrolide therapy. Respiration 1996;63:42-48
50. Oishi K, Sonoda F, Kobayashi S, et al. Role of interleukin-8 (IL-8) and an inhibitory effect of erythromycin on IL-8 release in the airways of patients with chronic airway diseases. Infect Immun 1994;62:4145-4152
51. Kusano S, Kadota J, Kohno S, et al. Effect of roxithromycin on peripheral neutrophil adhesion molecules in patients with chronic lower respiratory tract disease. Respiration 1995;62:217-222
52. Beringer PM. New approaches to optimizing antimicrobial therapy in patients with cystic fibrosis. Curr Opin Pulm Med 1999;5:371-377
53. Konstan MW. Therapies aimed at airway inflammation in cystic fibrosis. Clin Chest Med 1998;19:505-513
54. Akira M, Kitatani F, Lee YS, et al. Diffuse panbronchiolitis: evaluation with high-resolution CT. Radiology 1988;168:433-438
55. Nishimura K, Kitaichi M, Izumi T, Itoh H. Diffuse panbronchiolitis: correlation of high-resolution CT and pathologic findings. Radiology 1992;184:779-785
56. Hansell DM. Small airways diseases: detection and insights with computed tomography. Eur Respir J 2001;17:1294-1313
57. Takizawa H, Tadokoro K, Miyoshi Y, et al. Serological characterization of cold agglutinin in patients with diffuse panbronchiolitis [in Japanese]. Nihon Kyobu Shikkan Gakkai Zasshi 1986;24:257-263
58. Koyama H, Nishimura K, Mio T, Ikeda A, Sugiura N, Izumi T. Bronchial responsiveness and acute bronchodilator response in chronic obstructive pulmonary disease and diffuse panbronchiolitis. Thorax 1994;49:540-544
59. Nakata K. Revision of clinical guidelines for DPB [author's transl] [in Japanese]. Annual Report on the study of diffuse lung disease in 1998. Tokyo:Grant-in Aid from the Ministry of Health and Welfare of Japan; 1999:109-111
60. Sawaki M, Mikami R, Mikasa K, Kunimatsu M, Ito S, Narita N. The long-term chemotherapy with erythromycin in chronic lower respiratory tract infections-first report: comparison with amoxicillin [in Japanese]. Kansenshogaku Zasshi 1986;60:37-44
61. Yamamoto M, Kondo A, Tamura M, Izumi T, Ina Y, Noda M. Long-term therapeutic effects of erythromycin and newquinolone antibacterial agents on diffuse panbronchiolitis [in Japanese]. Nihon Kyobu Shikkan Gakkai Zasshi 1990;28:1305-1313
62. Nagai H, Shishido H, Yoneda R, Yamaguchi E, Tamura A, Kurashima A. Long-term low-dose administration of erythromycin to patients with diffuse panbronchiolitis. Respiration 1991;58:145-149
63. Fujii T, Kadota J, Kawakami K, et al. Long-term effect of erythromycin therapy in patients with chronic Pseudomonas aeruginosa infection. Thorax 1995;50:1246-1252
64. Yamada G, Igarashi T, Itoh E, Tanaka H, Sekine K, Abe S. Centrilobular nodules correlate with air trapping in diffuse panbronchiolitis during erythromycin therapy. Chest 2001;120:198-202
65. Ichikawa Y, Hotta M, Sumita S, Fujimoto K, Oizumi K. Reversible airway lesions in diffuse panbronchiolitis: detection by high-resolution computed tomography. Chest 1995;107:120-125
66. Akira M, Higashihara T, Sakatani M, Hara H. Diffuse panbronchiolitis: follow-up CT examination. Radiology 1993;189:559-562
67. Sawaki M, Mikami R, Mikasa K, Kunimatsu M, Ito S, Narita N. The long-term chemotherapy with erythromycin in chronic lower respiratory tract infections-second report: including cases with Pseudomonas infections [in Japanese]. Kansenshogaku Zasshi 1986;60:45-50
68. Yamamoto M. A double-blind placebo-controlled study on the therapeutic effect of erythromycin on DPB [author's transl.] [in Japanese]. Annual Report on the study of diffuse lung disease in 1990 [in Japanese]. Tokyo: Grant-in Aid from the Ministry of Health and Welfare of Japan; 1991:18-20
69. Kudoh S, Azuma A, Yamamoto M, Izumi T, Ando M. Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin. Am J Respir Crit Care Med 1998;157(6 Pt 1):1829-1832
70. Nakamura H, Fujishima S, Inoue T, et al. Clinical and immunoregulatory effects of roxithromycin therapy for chronic respiratory tract infection. Eur Respir J 1999;13:1371-1379
71. Mikasa K, Sawaki M, Kita E, et al. Long-term chemotherapy using erythromycin (EM) for chronic lower airway infection: effectiveness of clarithromycin in EM ineffective cases-the fourth report [in Japanese]. Kansenshogaku Zasshi 1992;66:1097-10104
72. Tamaoki J, Takeyama K, Tagaya E, Konno K. Effect of clarithromycin on sputum production and its rheological properties in chronic respiratory tract infections. Antimicrob Agents Chemother 1995;39:1688-1690
73. Shirai T, Sato A, Chida K. Effect of 14-membered ring macrolide therapy on chronic respiratory tract infections and polymorphonuclear leukocyte activity. Intern Med 1995;34:469-474
74. Nakata K, Taguchi Y, Kudoh S. Therapeutic guidelines for DPB [author's transl.] [in Japanese]. Annual Report on the study of diffuse lung disease in 1999. Tokyo: Grant-in Aid from the Ministry of Health and Welfare of Japan; 2000:111
75. Kudoh S. Erythromycin treatment in diffuse panbronchiolitis. Curr Opin Pulm Med 1998;4:116-121
76. Koyama H, Geddes DM. Erythromycin and diffuse panbronchiolitis. Thorax 1997;52:915-918
77. Jaffe A, Bush A. Anti-inflammatory effects of macrolides in lung disease. Pediatr Pulmonol 2001;31:464-473
78. Rubin BK, Tamaoki J. Macrolide antibiotics as biological response modifiers. Curr Opin Investig Drugs 2000;1:169-172
79. Kadota J. Antiinflammatory effects of macrolide therapy in patients with diffuse panbronchiolitis, a chronic inflammatory airway disease. Recent Res Devel Antimicrob Agents & Chemother 1999;3(Pt 1):17-38
80. Wales D, Woodhead M. The anti-inflammatory effects of macrolides. Thorax 1999;54(suppl 2):S58-S62
81. Yanagihara K, Kadoto J, Kohno S. Diffuse panbronchiolitis: pathophysiology and treatment mechanisms. Int J Antimicrob Agents 2001;18(suppl 1):83-87
82. Labro MT. Anti-inflammatory activity of macrolides: a new therapeutic potential? J Antimicrob Chemother 1998;41(suppl B):37-46
83. Hoyt JC, Robbins RA. Macrolide antibiotics and pulmonary inflammation. FEMS Microbiol Lett 2001;205:1-7
84. Culic O, Erakovic V, Parnham MJ. Anti-inflammatory effects of macrolide antibiotics. Eur J Pharmacol 2001;429:209-229
85. Azuma A. Novel activity of erythromycin derivatives on inflammatory lung diseases. Recent Res Devel Respir Crit Care Med 2001;1:191-207
86. Rubin BK, Druce H, Ramirez OE, Palmer R. Effect of clarithromycin on nasal mucus properties in healthy subjects and in patients with purulent rhinitis. Am J Respir Crit Care Med 1997;155:2018-2123
87. Tamaoki J, Isono K, Sakai N, Kanemura T, Konno K. Erythromycin inhibits Cl secretion across canine tracheal epithelial cells. Eur Respir J 1992;5:234-238
88. Kondo M, Kanoh S, Tamaoki J, Shirakawa H, Miyazaki S, Nagai A. Erythromycin inhibits ATP-induced intracellular calcium responses in bovine tracheal epithelial cells. Am J Respir Cell Mol Biol 1998;19:799-804
89. Zhao DM, Xue HH, Chida K, et al. Effect of erythromycin on ATP-induced intracellular calcium response in A549 cells. Am J Physiol Lung Cell Mol Physiol 2000;278:L726-736
90. Hojo M, Fujita I, Hamasaki Y, Miyazaki M, Miyazaki S. Erythromycin does not directly affect neutrophil functions. Chest 1994;105:520-523
91. Mitsuyama T, Hidaka K, Furuno T, Hara N. Neutrophil-induced endothelial cell damage: inhibition by a 14-membered ring macrolide through the action of nitric oxide. Int Arch Allergy Immunol 1997;114:111-115
92. Takizawa H, Desaki M, Ohtoshi T, et al. Erythromycin modulates IL-8 expression in normal and inflamed human bronchial epithelial cells. Am J Respir Crit Care Med 1997;156:266-271
93. Desaki M, Takizawa H, Ohtoshi T, et al. Erythromycin suppresses nuclear factor-kappaB and activator protein-1 activation in human bronchial epithelial cells. Biochem Biophys Res Commun 2000;267:124-128
94. Aoki Y, Kao PN. Erythromycin inhibits transcriptional activation of NF-kappaB, but not NFAT, through calcineurin-independent signaling in T cells. Antimicrob Agents Chemother 1999;43:2678-2684
95. Abe S, Nakamura H, Inoue S, et al. Interleukin-8 gene repression by clarithromycin is mediated by the activator protein-1 binding site in human bronchial epithelial cells. Am J Respir Cell Mol Biol 2000;22:51-60
96. Khair OA, Devalia JL, Abdelaziz MM, Sapsford RJ, Davies RJ. Effect of erythromycin on Haemophilus influenzae endotoxin-induced release of IL-6, IL-8 and sICAIM-1 by cultured human bronchial epithelial cells. Eur Respir J 1995;8:1451-1457
97. Keicho N, Kudoh S, Yotsumoto H, Akagawa KS. Antilymphocytic activity of erythromycin distinct from that of FK506 or cyclosporin A. J Antibiot (Tokyo) 1993;46:1406-1413
98. Morikawa K, Oseko F, Morikawa S, Iwamoto K. Immunomodulatory effects of three macrolides, midecamycin acetate, josamycin, and clarithromycin, on human T-lymphocyte function in vitro. Antimicrob Agents Chemother 1994;38:2643-2647
99. Kita E, Sawaki M, Nishikawa F, et al. Enhanced interleukin production after long-term administration of erythromycin stearate. Pharmacology 1990;41:177-183
100. Sugiyama Y, Yanagisawa K, Tominaga SI, Kitamura S. Effects of long-term administration of erythromycin on cytokine production in rat alveolar macrophages. Eur Respir J 1999;14:1113-1116
101. Tamaoki J, Kondo M, Kohri K, Aoshiba K, Tagaya E, Nagai A. Macrolide antibiotics protect against immune complex-induced lung injury in rats: role of nitric oxide from alveolar macrophages. J Immunol 1999;163:2909-2915
102. Keicho N, Kudoh S, Yotsumoto H, Akagawa KS. Erythromycin promotes monocyte to macrophage differentiation. J Antibiot (Tokyo) 1994;47:80-89
103. Howe RA, Spencer RC. Macrolides for the treatment of Pseudomonas aeruginosa infections? J Antimicrob Chemother 1997;40:153-155
104. Kita E, Sawaki M, Oku D, et al. Suppression of virulence factors of Pseudomonas aeruginosa by erythromycin. J Antimicrob Chemother 1991;27:273-284
105. Sakata K, Yajima H, Tanaka K, et al. Erythromycin inhibits the production of elastase by Pseudomonas aeruginosa without affecting its proliferation in vitro. Am Rev Respir Dis 1993;148(4 Pt 1):1061-1065
106. Molinari G, Guzman CA, Pesce A, Schito GC. Inhibition of Pseudomonas aeruginosa virulence factors by subinhibitory concentrations of azithromycin and other macrolide antibiotics. J Antimicrob Chemother 1993;31:681-688
107. Kobayashi H. Biofilm disease: its clinical manifestation and therapeutic possibilities of macrolides. Am J Med 1995;99(6A):26S-30S
108. Davies DG, Parsek MR, Pearson JP, Iglewski BH, Costerton JW, Greenberg EP. The involvement of cell-to-cell signals in the development of a bacterial biofilm. Science 1998;280:295-298
109. Tateda K, Comte R, Pechere JC, Kohler T, Yamaguchi K, Van Delden C. Azithromycin inhibits quorum sensing in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2001;45:1930-1933